Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Champions Oncology, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 29 | 1 | 23 | −5 |
| Shares | 5.74M | 775 | 5.61M | −125.6K (−2.2%) |
| Value | $35.6M | $4.00K | $31.5M | −$4.15M (−11.6%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Champions Oncology, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
None.
Sold out (5)
Institutions that held Champions Oncology, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Overbrook Management Corp | 48,488 | $301.1K |
| Millennium Management LLC | 33,466 | $208.2K |
| Stifel Financial Corp | 10,442 | $64.8K |
| Simplex Trading, LLC | 1,064 | $6.00K |
| Tower Research Capital LLC (TRC) | 21 | $130 |
Not filed for Q4 2023 yet (1)
Institutions that held Champions Oncology, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Steward Financial Group LLC | 775 | $4.00K |